Cencora, Inc. (COR) Stock Price & How to Invest

Cencora buys pharmaceuticals from manufacturers and delivers them to pharmacies, hospitals, physician practices and clinics, taking a fee measured in fractions of a percent on each transaction. Roughly 90 percent of revenue sits in the U.S. Healthcare Solutions segment, where specialty products (oncology drugs, biologics, cell and gene therapies) carry better economics than traditional generics and now anchor the growth rate. International Healthcare Solutions covers distribution and specialty logistics across Europe and Canada, and the smaller Other segment holds MWI Animal Health and Brazil's Profarma. The company employs roughly 47,000 people and was known as AmerisourceBergen until August 2023.

The investment picture turns on a single structural fact: on ~$333 billion of trailing revenue, gross margin is around 3 percent and operating margin sits near 1 percent. Small changes in product mix therefore swing profit hard, which is why management talks constantly about specialty share and why the surge in GLP-1 volume has been a revenue tailwind and a margin headwind at the same time. Fiscal 2026 has gone well by the company's own measure: third-quarter revenue of ~$84.8 billion rose ~5 percent, adjusted diluted EPS climbed ~12 percent, and the full-year adjusted EPS range was raised to ~$17.75 to ~$17.95. Cencora is also pushing downstream into the practices it supplies, closing a ~$5 billion majority stake in OneOncology in early 2026 and agreeing to buy EyeSouth Partners' retina business for ~$1.1 billion, which raises leverage and integration risk in exchange for owning more of the specialty economics.

Customer concentration is the sharpest exposure: a small number of relationships, including Walgreens and Evernorth, account for a large share of revenue, so a contract renegotiation or loss would be felt immediately. Opioid litigation obligations are a known and quantified drag rather than an open question: as part of the nationwide distributor settlement announced in 2021, the company (then AmerisourceBergen) agreed to pay roughly $6.4 billion spread over 18 years, and those payments run into the late 2030s alongside a separate $40 million data breach class action settlement resolved in 2025. Margin structure leaves almost no cushion, so a mix shift toward low-fee products such as GLP-1 therapies, or any policy change to drug pricing and reimbursement, compresses profit faster than the revenue line suggests. The move into owning oncology and ophthalmology practices adds integration risk, meaningful debt (including a $3.0 billion notes offering in February 2026 to fund OneOncology), and the possibility of antitrust or regulatory attention to a distributor that also owns providers. A CFO transition completed in mid-2026, with Eva Boratto succeeding James Cleary, adds ordinary execution uncertainty at the top of the finance function.

12 analysts publish price targets on COR, averaging $372.58 against a $325.00 price as of August 2026, or +14.6%. The published targets run from $330.00 to $430.00, a narrow spread, and the ratings split 12 buy, 2 hold, 0 sell. Over the last six months there have been 7 raises and 5 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full COR forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Cencora, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Specialty volume, not overall drug volume. Oncology, biologics and other specialty therapies carry higher fees per unit and require handling that a general logistics firm cannot easily replicate, from cold chain to limited-distribution networks. The most optimistic published target, $430.00, assumes this works close to its best case.

The case against. Customer concentration is the sharpest exposure: a small number of relationships, including Walgreens and Evernorth, account for a large share of revenue, so a contract renegotiation or loss would be felt immediately. The most pessimistic target, $330.00, is roughly what COR is worth if this bites instead.

Read the full bull and bear case on COR, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Cencora, Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$333 billion
• Fiscal Q3 2026 revenue: ~$84.8 billion, up ~5% year over year
• Adjusted diluted EPS (FY2026 guidance): ~$17.75 to ~$17.95
• Market capitalization: ~$62 billion
• Forward P/E on FY2026 adjusted EPS: ~18x (trailing GAAP P/E ~24x)
• Gross margin: ~3% of revenue; operating margin near ~1%

The gap between a ~$333 billion top line and a ~$62 billion market value is the whole point of the business model, and reading the revenue figure as a measure of scale in the usual sense will mislead. Cencora keeps roughly three cents of gross profit per dollar of product it moves and about one cent of operating profit, so valuation is set off earnings and free cash flow rather than any revenue multiple. At recent prices the shares trade around 18 times the midpoint of fiscal 2026 adjusted EPS guidance, which sits close to where McKesson and Cardinal Health have traded through the same stretch.

If you want COR exposure as part of a larger bundle rather than directly, these ETFs hold it meaningfully. Weights are approximate and refresh quarterly.

Other names that sit close to COR: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get COR exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it (RWL), which spreads the position across many companies. Or build it into a focused thematic portfolio, so COR sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where COR fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

COR is a penny-margin logistics business with a hard-to-replicate specialty franchise, priced at roughly 18 times fiscal 2026 adjusted earnings, and the case for it rests on volume durability rather than on the enormous top line.

Whether COR is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is COR a buy or a sell?, and where the stock could go from here in the COR stock forecast.

For income investors, whether COR pays a dividend and how the payout looks is covered in does COR pay a dividend? And to weigh COR against a peer, read the full side-by-side comparisons: COR vs MCK and COR vs UNH.